Vera Therapeutics (VERA) Income from Continuing Operations (2020 - 2026)
Vera Therapeutics posted quarterly Income from Continuing Operations of 120600000.0 for Q1 2026, down 131.57% year-on-year from 382046715.33 in Q1 2025, and down 33.12% on a QoQ basis from 90593000.0 in Q4 2025.
Vera Therapeutics (VERA) has 7 years of Income from Continuing Operations data on file, last reported at 120600000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 131.57% year-over-year to 120600000.0; the trailing twelve-month figure through Mar 2026 stood at 367044000.0 (down 771.63% YoY), and the FY2025 full-year result was 1000.0, up 100.0% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 120600000.0, down from 90593000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 91097000.0 in Q4 2024 and bottomed at 120600000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 28832000.0 (2024), against an average of 27758529.41.
- Peak annual rise in Income from Continuing Operations reached 334.44% in 2022, while the deepest fall reached 263.03% in 2022.
- A 5-year view of Income from Continuing Operations shows it stood at 38915000.0 in 2022, then surged by 43.21% to 55730000.0 in 2023, then soared by 63.46% to 91097000.0 in 2024, then sank by 199.45% to 90593000.0 in 2025, then sank by 33.12% to 120600000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 120600000.0 (Q1 2026), 90593000.0 (Q4 2025), and 80156000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Vera Therapeutics | 2.43 Bn | 1.83 Bn | - | -120.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -120.60 Mn |
| Dec 31, 2025 | -90.59 Mn |
| Sep 30, 2025 | -80.16 Mn |
| Jun 30, 2025 | -75.70 Mn |
| Mar 31, 2025 | -52.08 Mn |
| Dec 31, 2024 | 91.10 Mn |
| Sep 30, 2024 | -46.98 Mn |
| Jun 30, 2024 | -34.15 Mn |
| Mar 31, 2024 | -28.83 Mn |
| Dec 31, 2023 | 55.73 Mn |
| Sep 30, 2023 | -20.54 Mn |
| Jun 30, 2023 | -20.65 Mn |
| Mar 31, 2023 | -30.51 Mn |
| Dec 31, 2022 | 38.92 Mn |
| Sep 30, 2022 | -24.82 Mn |
| Jun 30, 2022 | -14.92 Mn |
| Mar 31, 2022 | -17.11 Mn |
| Dec 31, 2021 | -16.60 Mn |
| Sep 30, 2021 | -7.25 Mn |
| Jun 30, 2021 | -5.85 Mn |
| Mar 31, 2021 | -4.71 Mn |
| Dec 31, 2020 | -42.57 Mn |
| Sep 30, 2020 | -4.10 Mn |
| Jun 30, 2020 | -3.24 Mn |
| Mar 31, 2020 | -2.49 Mn |